Heterologous production of chondroitin

Márcia R. Couto a, b, Joana L. Rodrigues a, b, *, Lígia R. Rodrigues a, b

a Centre of Biological Engineering, University of Minho, Braga, Portugal
b LABBELS – Associate Laboratory, Braga, Guimarães, Portugal

ARTICLE INFO

Keywords:
Chondroitin
Glycosaminoglycans
Bio synt hetic pathway
Metabolic engineering
Microbial fermentation
Heterologous production

ABSTRACT

Chondroitin sulfate (CS) is a glycosaminoglycan with a broad range of applications being a popular dietary supplement for osteoarthritis. Usually, CS is extracted from animal sources. However, the known risks of animal products use have been driving the search for alternative methods and sources to obtain this compound. Several pathogenic bacteria naturally produce chondroitin-like polysaccharides through well-known pathways and, therefore, have been the basis for numerous studies that aim to produce chondroitin using non-pathogenic hosts. However, the yields obtained are not enough to meet the high demand for this glycosaminoglycan. Metabolic engineering strategies have been used to construct improved heterologous hosts. The identification of metabolic bottlenecks and regulation points, and the screening for efficient enzymes are key points for constructing microbial cell factories with improved chondroitin yields to achieve industrial CS production. The recent advances on enzymatic and microbial strategies to produce non-animal chondroitin are herein reviewed. Challenges and prospects for future research are also discussed.

1. Introduction

Glycosaminoglycans (GAGs) are naturally occurring heteropolysaccharides with polyanionic character. They consist of repeating disaccharide units composed of an N-acetylated or N-sulfated hexosamine (glucosamine, GlcN or galactosamine, GalN) and either a uronic acid (glucuronic acid, GlcA or iduronic acid, IdoA) or galactose (Gal). There are four main types of GAGs that vary in their monomeric composition, glycosidic bonds and sulfation pattern: hyaluronic acid (hyaluronate, hyaluronan, HA); keratan sulfate (KS); chondroitin sulfate/dermatan sulfate (CS/DS, stereoisomers); and heparin/heparan sulfate (HP/HS) [1]. The chemical structures of the repeating disaccharide units of different GAGs are represented in Fig. 1. While HA lacks sulfate groups, the remaining GAGs can contain sulfates at various positions. DS is distinguished from CS by the presence of IdoA. HS is the only glycosaminoglycan that contains a N-sulfated hexosamine and differs from HP by possessing less sulfated units and less content of epimerized entities into IdoA. Heparan is the non-sulfated precursor to HS and HP. Keratan sulfate lacks uronic acids and instead contains sulfated Gal residues.

In animals, GAGs usually exist as long chains covalently bound to a protein core, as part of proteoglycans [2]. Depending on their molecular structure, GAGs have a wide distribution through tissues and perform different physiologic functions including in structural support, cell recognition and signaling, matrix organization, inflammation, cell division, and tissue repair and development [3, 4], being particularly common in connective tissues such as the skin, bone, cartilage, and the intervertebral discs [5]. Some bacterial pathogens produce GAG-like polysaccharides as part of their capsule composition, which contribute to their pathogenicity [6-8].

The wide applications of GAGs in medicine, veterinary, cosmetics, and pharmaceuticals have been extensively reviewed [5, 9, 10]. The most famous GAG clinical application is the use of HP as an anticoagulant drug. Furthermore, GAGs also exist as nutraceuticals in human and veterinary supplements, serve as cosmetic or pharmaceutical ingredients, or act as materials for several biomedical applications such as tissue engineering.

The industrial production of GAGs can be classified in 4 types: (i) extraction from animal sources; (ii) chemical synthesis; (iii) enzymatic or chemoenzymatic production or (iv) microbial or animal cells fermentation. Regarding microbial fermentation, the industrial production of HA is currently the most well established due to its simple structure that does not undergo sulfation or epimerization contrarily to the other GAGs. However, sulfated GAGs such as CS, HS, HP and KS are usually chemically extracted from animal sources, through a laborious process that requires a large amount of environmentally hazardous
compounds [11, 12]. Also, the use of animal sources brings concerns on contamination with other animal products, viruses, and prions. In addition, religious motivations and vegetarianism trends have also led to the search for non-animal sources [13].

This review is focused on the recent advances of production processes for animal-free chondroitin and CS production, including enzymatic and microbial strategies, which are areas with great advances in the last few years. With the increasing knowledge on biosynthesis, regulation, transportation, bottlenecks, metabolic engineering strategies, bioprocess optimization, and with the discovery of new enzymes, a sustainable process for the microbial production of value-added natural and artificial chondroitin derivatives is closer to becoming a reality.

2. Occurrence and biological functions of chondroitin and its derivatives

Chondroitin is the unsulfated precursor of CS, the most abundant GAG in the human body. It comprises a repeated disaccharide structurally composed by a glucuronic acid (GlcA) residue and a N-acetyl-Galactosamine (GalNAc) residue linked by β(1→3) and β(1→4) bonds, respectively (Fig. 1, Table 1). According to its sulfation pattern, CS is mainly classified into CS-A, CS-C, CS-D, CS-E and CS-O (unsulfated chondroitin) [2, 14]. However, novel CS disaccharide units have been discovered in natural sources (CS-F, CS-G, CS-K, CS-L, CS-M, CS-S and CS-T) [15-17] or chemically synthesized (CS-R, CS-U and CS-V) [18]. Considered by some authors as a type of CS, DS (CS-B) is distinguished by the presence of at least one IdoA residue, resulting from the epimerization of GlcA. In higher animals, CS exists anchored to proteins as part of proteoglycans, being the predominant types CS-A and CS-C, and is present in connective tissues, for example, cartilage, cornea, bone, skin, arterial walls [19]. Examples of natural sources of CS and DS are presented in Table 1. CS has biological roles in inflammation prevention, immune modulation, maintenance of the structure, elasticity and shock-absorbing properties of cartilage, regulation of cell adhesion to the extracellular matrix, facilitation of nutrient and oxygen diffusion, mediation of tumor growth and metastasis, pathogen adhesion, angiogenesis, osteogenic differentiation and in brain development, plasticity and regeneration [20, 21 - 23, 24]. Interestingly, CS biological functions depend on the chain length, sulfation pattern and percentage of the structural units, which vary upon animal age and tissue. DS is predominant in skin, heart valve, tendons, and blood vessels [25, 26, 27].

The physiologic roles of DS include regulation of transforming growth factor-β activity, cell proliferation, cell development, cell adhesion, homeostasis, collagen organization, anticoagulant activity, tumorogenesis, infection, wound repair, fibrosis and stabilization of the basement membrane [25, 28, 29, 30, 31, 32]. Particularly, the well-studied anticoagulant activity of DS occurs by its binding to HP cofactor II. The resulting complex can inhibit the procoagulant effect of thrombin, while not affecting the clotting cascade (factor X) or the platelet function. DS selective inhibition of thrombin makes it an interesting alternative to HP [33, 34].

In bacteria, unsulfated chondroitin backbone is produced as capsular polysaccharide by pathogens Pasteurella multocida Type F and Avibacterium paragallinarum genotype I [35, 36], while a chondroitin decorated with fructose residues is produced by Escherichia coli K4 [37]. Bacteria use these capsular polysaccharides to mask their infection and repellents [30-32].

![Fig. 1. Structures of the main glycosaminoglycans (GAGs) a) hyaluronic acid, b) keratan sulfate, c) chondroitin and chondroitin sulfate, d) dermatan sulfate, and e) heparan sulfate and heparin. Monomers of the disaccharide building blocks are abbreviated as GlcA - 6-glucuronic acid, GlcNAc - N-acetyl-D-glucosamine, Gal – D-galactose, GalNAc – N-acetyl-D-galactosamine, IdoA – D-iduronic acid, GlcN – D-glucosamine. Hyaluronic acid (a) does not go under post-polymerization modifications. Keratan sulfate (b) has di-sulfated, mono-sulfated and non-sulfated disaccharide units (each R^6 = H or SO_3H) due to O-sulfotransferases action. Chondroitin (c) is the simple non-sulfated backbone (R^2, R^3, R^4 and R^6 = H or SO_3H). Dermatan sulfate (d) is formed from chondroitin through epimerization of GlcA into IdoA by tissue-specific epimerases followed by O-sulfotransferases action. Heparin (e) is a complex disaccharide (R^2, R^3 and R^6 = H or SO_3H). Heparin has more sulfate groups and IdoA content than heparan sulfate. Depending on the GAG type and source the molecular size can generally vary between 4 and 200 mer (n = 4 – 200). Exceptionally, the highest size can be found for hyaluronic acid that can achieve 20,000 repeating units.](image-url)
and tissue used. Some of the reported CS yields include: extraction from artificial synthesis of the chondroitin backbone, either using chemical by-products, yields from 19 to 137 mg/g dry cartilage have been achieved (fCS) yields varied from 63 to 110 mg/g weight [54] ; and from fish lage were obtained [70] ; from different sea cucumbers, fucosylated CS [68] ; 75 mg/g of dry weight has been achieved by extraction from ray sternum, trachea cartilages generated 91

Examples of natural sources of different types of chondroitin, chondroitin sulfate (CS), and dermatan sulfate (DS) and their biological functions in humans. In higher animals, different types of GAGs can occur in different proportions and sizes depending for example on the animal, tissue, age or diet.

| GAG type                  | Disaccharide repeat | Natural sources                        | Biological functions                                                                 | References |
|---------------------------|--------------------|----------------------------------------|---------------------------------------------------------------------------------------|------------|
| CS-A                      | GlcA(1→3)GalNAc(4S)(1→4) | Dogfish, shark and whale cartilage; human, bovine, porcine and chicken cartilaginous tissues | regulates axonal guidance and growth; activates metastatic cascade                     | [13, 22, 38, 39, 40] |
| CS-B (DS)                 | GlcA/IdoA(2S)(1→3)GalNAc (4S)(1→4) | Animal skin/hide, cornea, cartilage, heart valve, tendons, blood vessels, and bone | regulates growth factors activity; has anticoagulant activity; promotes proliferation of several cell lines; mediates homeostasis, tumorigenesis, infection, wound repair, collagen organization, fibrosis and stabilization of the basement membrane | [25, 26, 27, 28, 29, 30, 31, 32] |
| CS-C                      | GlcA(1→3)GalNAc(6S)(1→4) | Dogfish and shark cartilage; human, bovine, porcine and chicken cartilaginous tissues | may promote progression of epilepsy; neuroprotective properties in Alzheimer’s disease | [13, 38, 41, 42, 43] |
| CS-D                      | GlcA(2S)(1→3)GalNAc(6S) (1→4) | Shark cartilage; animal brain | promotes neuron growth; interacts with humoral factors | [22, 44, 45, 46] |
| CS-E                      | GlcA(1→3)GalNAc(4, 6dis) (1→4) | Squid cartilage; animal lung | mediates angiogenesis; acts as cell surface receptor for herpes virus; modulates humoral factors; stimulates neurite outgrowth; promotes neural stem cells proliferation; mediates osteogenic differentiation | [22, 24, 32, 46, 47, 48] |
| Fucosylated CS           | different types of CS with υ-fucosyl branches usually attached to the O-3 of GlcA unit | Sea cucumbers | – | [49, 50, 51, 52, 53, 54] |
| CS-G                      | different types of CS with glucose attached to the O-6 of GalNAc unit | Squid cartilage | – | [55] |
| CS-H (highly sulfated DS) | IdOAc(1→3)GalNAc(4S, 6S) (1→4) | Hagfish notochord | – | [56] |
| CS-L                      | GlcA(3S)(1→3)GalNAc(4S) (1→4) | Squid, king crab and octopus | – | [57, 58, 59, 60] |
| CS-M                      | GlcA(3S)(1→3)GalNAc(6S) (1→4) | Squid | – | [60] |
| Unsulfated chondroitin    | GlcA(1→3)GalNAc(1→4) Pasteurella multocida Type F; Avibacterium paragallinarum genotype 1 | Squid | – | [35, 36] |
| N-glycolyl chondroitin    | GlcA(3Fru)(1→3) GalNAc(1→4) E. coli K4 | Squid | – | [37, 61, 62, 63, 64, 65] |
| N-glycolyl chondroitin    | GlcA(1→3)GalNGe(1→4) | Serum of humans who eat red meat (beef, lamb, and pork) | – | [66] |

thus increase their pathogenicity [6].

Commercial CS is usually provided as a mixture of CS-A and CS-C, the most common CS in animal cartilage [67], which is obtained through chemical extraction and purification from animal cartilaginous tissues, mainly from bovine, porcine, shark and chicken. The structural composition, molecular weight and yields of CS obtained from extraction vary not only with the extraction method but also with the animal and tissue used. Some of the reported CS yields include: extraction from shark fin resulted in 150.5 mg/g dry cartilage [68]; from blue shark head wastes 120.8 mg/g dry cartilage was obtained; crocodile hyoid, rib, sternum, trachea cartilages generated 91 – 274 mg/g of dry cartilage [68]; 75 mg/g of dry weight has been achieved by extraction from ray [68]; buffalo nasal, joint and tracheal cartilages generated 60 to 62 mg/g of dry cartilage [69]; using chicken keel, 24.8 mg/g of wet cartilage were obtained [70]; from different sea cucumbers, fucosylated CS (ICS) yields varied from 63 to 110 mg/g weight [54]; and from fish by-products, yields from 19 to 137 mg/g dry cartilage have been achieved [71]. In addition to the relatively low yields, the shortage of such materials and the concerns on intraspecies contamination led to studies on artificial synthesis of the chondroitin backbone, either using chemical synthesis, enzymatic, chemo-enzymatic and microbial fermentation strategies.

3. Clinical applications of CS

Given the growing potential applications of CS, and the rising prevalence of osteoarthritis due to the increase in average life expectancy among the population, a boost in its demand and market volume has been registered. The global CS market size was valued as USD 1.17 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 3.0% from 2020 to 2028 [72]. In 2018, China was the biggest producer accounting for 83.7% of CS produced globally [73].

Depending on their application, different systems have been implemented for the administration of chondroitin and its derivatives, including oral administration as food additives, in pharmaceutical preparations, nutraceuticals or veterinary supplements [74, 75, 76, 77]; incorporation in intra-articular or intravenous injectables [78]; integration in skin dermatology/cosmeceutical and ophthalmic products [79, 80, 81]; as part of medical devices [82, 83, 84, 85]; or as biomaterials for regenerative medicine [9, 86].

The current main application of CS is as nutraceutical to treat osteoarthritis symptoms and retard cartilage degradation [77, 87]. These supplements have been widely prescribed for humans and animals and are usually formulated with glucosamine. Although the results on the efficacy of chondroitin or its combination with glucosamine in joint repair and pain relief compared with placebo have not always been concurrent [86, 89, 90, 91], CS and glucosamine have been recommended in guidelines, prescribed by general practitioners and rheumatologists as over-the-counter drugs and suggested by the European League Against Rheumatism (EULAR) to patients with knee and hand osteoarthritis [92]. The variable efficacy of CS is in part attributed to its highly variable composition. Since they are over-the-counter supplements, they are not tightly controlled and can differ in the biological source, purification method and ingredient amount and type, thus...
resulting in heterogenous CS mixtures with different sulfation patterns or even containing other GAGs as contaminants. Condrosulf (fish CS, IBSA Institut Biochimique SA, Lugano, Switzerland), Condrosan (bovine CS, Bioiberica S.A.U, Barcelona, Spain), and Structum (avian CS, Laboratoires Pierre Fabre, Paris, France) are examples of commercialized pharmaceutical-grade CS products that have shown benefits for osteoarthritis in clinical trials [93, 94, 95, 96, 97, 98, 99, 100]. In these studies, CS has shown to be safe and, generally, exhibited slight to moderate efficacy over placebo in pain relief and function improvement for osteoarthritis patients. Also, CS is included in eye drop solutions for dry eyes [79, 80]. Preservative-free ophthalmic solutions combining xanthan gum and CS or combining sodium HA and CS showed similar efficacy compared to polyethylene glycol and propylene glycol solutions in the treatment of dry eye disease. The CS oral supplementation in dry eyes [79, 80]. Preservative-free ophthalmic solutions combining moderate efficacy over placebo in pain relief and function improvement studies, CS has shown to be safe and, generally, exhibited slight to moderate efficacy over placebo in pain relief and function improvement for arthritis in clinical trials [93, 94, 95, 96, 97, 98, 99, 100]. In these studies, CS has shown to be safe and, generally, exhibited slight to moderate efficacy over placebo in pain relief and function improvement for osteoarthritis patients. Also, CS is included in eye drop solutions for dry eyes [79, 80]. Preservative-free ophthalmic solutions combining xanthan gum and CS or combining sodium HA and CS showed similar efficacy compared to polyethylene glycol and propylene glycol solutions in the treatment of dry eye disease. The CS oral supplementation in combination with glucosamine hydrochloride has also shown improved therapeutic benefits in reducing systemic inflammation in overweighted individuals, over placebo [101]. For interstitial cystitis, the intravesical therapy [101].

### Table 2

| Glycosaminoglycan                | Condition / Potential application                             | Clinical trials ID |
|----------------------------------|-----------------------------------------------------------------|-------------------|
| Chondroitin sulfate              | Osteoarthritis (knee, hand)                                    | NCT00291499       |
|                                  |                                                                 | [93]              |
|                                  |                                                                 | NCT00604539       |
|                                  |                                                                 | [55]              |
|                                  |                                                                 | NCT01354145       |
|                                  |                                                                 | [86, 97]          |
|                                  |                                                                 | NCT00955552       |
|                                  |                                                                 | [121]             |
|                                  |                                                                 | NCT01425853       |
|                                  |                                                                 | [122]             |
|                                  |                                                                 | NCT01899095       |
|                                  |                                                                 | [123]             |
|                                  |                                                                 | NCT02830919       |
|                                  |                                                                 | [124]             |
|                                  |                                                                 | NCT01271218       |
|                                  |                                                                 | [125]             |
|                                  |                                                                 | NCT00513422       |
|                                  |                                                                 | [126, 127]        |
|                                  | Inflammation reduction and prevention                           | NCT01682694       |
|                                  |                                                                 | [101]             |
|                                  | Interstitial cystitis                                           | NCT04268810       |
|                                  |                                                                 | [84]              |
|                                  | Dry eye                                                         | NCT01657253       |
|                                  |                                                                 | [79]              |
|                                  | Hemostasis in surgeries                                         | NCT03725098       |
|                                  |                                                                 | [128]             |
|                                  | Corneal storage medium                                          | NCT01657500       |
|                                  |                                                                 | [102]             |
| Chondroitin sulfate and hyaluronic acid | Knee osteoarthritis                                             | NCT04352322       |
|                                  |                                                                 | [129]             |
|                                  | Recurrent urinary tract infections                              | NCT02016118       |
|                                  | Adjvant during phacoeuensation                                  | NCT01387620       |
|                                  |                                                                 | [82]              |
|                                  |                                                                 | NCT02304861       |
|                                  | Post-surgical rehabilitation                                    | NCT03355651       |
|                                  |                                                                 | [130]             |
| Dermatan sulfate and heparan sulfate (mesoglycan) | Post-operative thrombosis                                      | NCT04481698       |
|                                  |                                                                 | [131]             |
| Dermatan sulfate and heparin (suloxide) | Anticoagulant                                                   | NCT04257487       |
|                                  |                                                                 | [132]             |
|                                  | Diabetic retinopathy                                            | NCT01295775       |
|                                  |                                                                 | [133]             |
|                                  | Diabetic kidney disease                                         | NCT00130312       |
|                                  | (albuminuria, nephropathy)                                      | NCT00130208       |
|                                  |                                                                 | [135]             |

4. **Enzymatic and chemoenzymatic CS production**

Enzymes can be used to produce CS oligosaccharides by degrading CS polymers or by synthesizing CS oligosaccharides/polymers through polymerization. The main advantages of using enzymes over chemical approaches is that enzymes catalyze stereoselective and regioselective reactions, potentially resulting in homogeneous CS in an eco-friendlier and faster manner [136, 137]. However, these enzymatic steps are often combined with chemical synthesis or modifications (chemo-enzymatic strategies) to either provide synthetic precursors or to perform the sulfation step. The depolymerizing/degrading enzymes and the polysaccharide substrates used are relatively inexpensive [136]. However, the commercial polysaccharides are usually from animal sources which raises the concerns already mentioned. The degrading enzymes will be briefly discussed since they can give insights on structural analysis of CS, and because they can perform the contrary polymerization reaction under certain conditions. Enzymatic synthesis of CS from natural and unnatural precursors is the alternative for the preparation of homogeneous CS that most resembles the biological process. However, the high cost of such precursors generally limits the industrial implementation of these enzymatic methods.

4.1. **Enzymatic depolymerization of CS polysaccharides**

CS depolymerizing enzymes able to produce CS oligosaccharides are CS lyases [138, 139, 140] and CS hydrolases [141]. While polysaccharide hydrolases are found in almost every organism, polysaccharide lyases do not occur in vertebrates. According to their substrate specificity, the polysaccharide lyases acting on CS can be classified into chondroitinasases ABC, AC, B, and C. They perform the depolymerization of CS/DS polymers via endolytic or exolytic β-elimination resulting mainly in unsaturated oligosaccharides [138, 140]. Prostates vulgaris, Flavobacterium heparinum (Pedobacter heparinus), Sphingomonas paucimobilis, Bacteroides stercoris, Pseudopseudobacter salutis (Pedobacter salutis), and Bacteroides thetaiotaomicron are some examples
of different CS lyase producers [138, 140, 142, 143]. Differently from CS lyases, CS hydrolases usually depolymerize CS with no unsaturated bonds formed, which make them more attractive for the enzymatic production of CS [1]. Some animal HA hydrolases, hyaluronidases, show depolymerizing activity against CS and some isoforms can only accept CS as substrate [144, 145]. Therefore, these hyaluronidases have been used to depolymerize CS polysaccharides to obtain CS oligosaccharides (Fig. 2a) up to tetrasaccharides. The substrate specificity of CS lyases and CS hydrolases can retrieve functional characterization of GAGs.

4.2. Enzymatic synthesis of CS oligosaccharides and polysaccharides

For synthesis of CS oligosaccharides and polysaccharides, degrading enzymes that in the reverse direction synthesize polymers (such as hyaluronidases, Fig. 2b), or synthases (such as glycosyltransferases, Fig. 2c) can be used. Further post-polymerization modifications of the chondroitin backbone are required to achieve the CS oligosaccharides or polysaccharides. Specialized CS sulfotransferases, including 4-′-phosphoadenosine-5′-sulfotransferase (C6OST), 6-O-sulfotransferase (C6OST), 2-O-sulfotransferase (2OST) and N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase (GalNAc4S-6OST), sulfate the chondroitin composing units in the presence of the co-factor 3′-phosphoadenosine-5′-phosphosulfate (PAPS) to generate CS with different sulfation patterns and consequently different biological activities.

Chemoenzymatic methods using HA or CS degrading enzymes in the anabolic direction for the production of CS and its derivatives have been established, by either ring-opening polyaddition [146, 147] or by transglycosylation reaction [148]. The works of Kobayashi et al. [146] and Fujikawa et al. [147] used testicular hyaluronidases from ovine or bovine to catalyze the synthesis of structurally defined CS (natural and unnatural) from chemically synthesized disaccharide oxazoline precursors which acted as transition state analogues. Kakizaki et al. [148] used immobilized bovine testicular hyaluronidase to produce hybrid polysaccharides composed by both HA and CS units. First, the hyaluronidase was used to prepare oligosaccharides by digestion of commercial CS and HA polysaccharides. The oligosaccharides were fluorolabeled (to facilitate analytical identification) generating pyridylaminated acceptors which underwent transglycosylation catalyzed by immobilized hyaluronidase using HA and CS donor polysaccharides. These methods enabled to control the molecular weight of the resulting CS and the construction of unnatural CS derivatives. However, the use of expensive sugar precursors and dedicated reactors, as well as the low product yields are drawbacks that limited large-scale application [149].

The discovery of microbial counterparts of glycosyltransferases in pathogenic bacteria further boosted the development of enzymatic strategies to produce chondroitin and CS. Bacterial glycosyltransferases used for chondroitin synthesis, also named chondroitin synthases or chondroitin polymerases, include PmCS from Pasteurella multocida and KfoC from E. coli K4 strains. These enzymes act by transferring alternate residues of GlcA and GalNAc, using uridine diphosphate (UDP)-GlcA and UDP-GalNAc as donors, to the nonreducing end of a chondroitin chain acceptor to form chondroitin oligosaccharide backbones (Fig. 2c). DeAngelis et al. [150] identified for the first time a microbial gene encoding the chondroitin synthase PmCS and cloned it in E. coli. The same authors further used this recombinant glycosyltransferase for in vitro production of chondroitin from the substrates UDP-GlcA and UDP-GalNAc [151]. Other microbial glycosyltransferase KfoC was used by Sugiura et al. [152] to produce chondroitin oligosaccharides (CS-O) by immobilized hyaluronidase using HA and CS donor polysaccharides.

Depolymerizing enzymes, such as animal hyaluronidases, can be used to obtain CS oligosaccharides from CS polysaccharides; b) the same type of enzymes is able to, under different conditions, polymerize the CS oligosaccharides through chemoenzymatic approaches. c) Bacterial glycosyltransferases (such as chondroitin synthase from Escherichia coli K4, KfoC, or from Pasteurella multocida type F, PmCS) act by transferring alternate residues of glucuronic acid (GlcA) and acetylgalactosamine (GalNAc), using uridine diphosphate (UDP)-GlcA and UDP-GalNAc as donors, to the nonreducing end of a chondroitin chain acceptor to elongate the chondroitin oligosaccharide polysaccharide backbones. Sulfotransferases such as 4-O-sulfotransferase (C4OST), 6-O-sulfotransferase (C6OST), N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase (GalNAc4S-6OST), and 2-O-sulfotransferase (2OST) that require the presence of 3′-phosphoadenosine-5′-phosphosulfate (PAPS) as sulfate donor, convert the unsulfated backbone (CS-O) in CS with different sulfation patterns such as CS-A, CS-C, CS-E and CS-T. Only CSs with a homogenous defined sulfation pattern are shown although a CS chain may have different CS units if a combination of sulfotransferases is used. Dashed arrows represent polymerization steps.
with controlled size from 7-mer to 16-mer. The authors first digested a commercial unsulfated chondroitin polymer with hyaluronidase to achieve even-numbered oligosaccharides. Further digestion with β-glucuronidase allowed to obtain odd-numbered oligosaccharides. The oligosaccharides were subjected to pyridylamination to facilitate their analysis. Then, two mutated recombinant KfoC enzymes were expressed each being selective for one of the substrates (UDP-GlcA or UDP-GalNAc) and the engineered enzymes, immobilized in beads, were used to elongate the chondroitin chain. The same group employed chemoenzymatic strategies for the preparation of CS oligosaccharides and polysaccharides with different sulfate patterns using the CS polymerase KfoC and recombinant sulftotransferases C4OST, C6OST, GalNAc4S-6OST and 2OST [153, 154, 155]. The chondroitin backbone was obtained by desulfating commercial CS from different sources and HEK293T cells were used to express the human sulfotransferases. However, the resulting products were heterogeneous, low amounts were achieved, and the process required laborious techniques for the separation of oligosaccharides with different sizes. Afterwards, the enzymatic production of 15 structurally diversified and homogeneous CS-A and CS-C oligosaccharides was achieved using KfoC expressed in E. coli BL21 [156]. Amounts of 4–30 mg of CS oligosaccharides were obtained. The authors also synthesized the expensive substrate UDP-GalNAc using Bifidobacterium longum N-acetylhexosamine kinase and human GalNAc pyrophosphorylase both expressed in E. coli BL21, which significantly reduced the process cost. Human C4OST and mouse C6OST were afterwards used for sulfation of chondroitin backbones. Sf9 insect cells were used to express C4OST and C6OST. The authors were unsuccessful expressing C6OST in E. coli which they rationalized to be due to the glycosylation being required for the sulftotransferase activity as shown in Yusa et al. [157]. Accordingly, attempts to express soluble mouse C4OST in E. coli were also unsuccessful, and C4OST and C6OST were effectively expressed and secreted by the Pichia pastoris [158]. However, active human C4OST has been expressed in E. coli BL21 and P. pastoris [159]. Those authors showed that the glycosylated and non-glycosylated forms of the enzyme had similar activities. More recently, the soluble expression of human C4OST enzyme was also achieved in E. coli K4 and in E. coli K-12 MG1655 [160].

In addition to the most common CS types, CS-A and CS-C, efforts to enzymatically produce alternative CS structures have resulted in the synthesis of CS-E. Despite the enzymatic synthesis of structurally heterogeneous CS-E polysaccharides has been primarily reported [161], the enzymatic production of homogenous CS-E oligosaccharides was more recently achieved [106]. The process included a serial elongation of p-nitrophenyl glucuronide (GlcA-pNP) with UDP-GalNAc using KfoC followed by the sulftotransferase modifications on the unsulfated backbone by C4OST and GalNAc4S-6OST. Mouse GalNAc4S-6OST was expressed in Sf9 cells, the glycosyltransferase KfoC and C4OST were expressed as in Li et al. [156] and the structural units UDP-GlcA, UDP-GalNAc, and the co-factor PAPS were synthesized by enzymatic approaches.

Another recently reported chemoenzymatic strategy for the synthesis of homogeneous chondroitin polymers combined stepwise oligosaccharides synthesis from GalNAc and GlcA units with further enzymatic polymerization by PmCS [162]. The authors showed that PmCS needs a suitable oligosaccharide (at least a chondroitin trisaccharide) as the acceptor to trigger the in vitro chondroitin chain polymerization. The polymers were further chemically sulfated to form CS.

The CS backbone is sulfated through enzymatic polymerization, enzymatic in vitro reactions can be used to participate in the post-polymerization modification of the chondroitin backbone. Rat aryl sulftotransferase IV (ASST IV) expressed in E. coli and mouse C4OST and C6OST sulftotransferases expressed in P. pastoris were used to modify a chondroitin backbone produced in vivo [158]. Instead of using sulftotransferases to add sulfate groups to the chondroitin, an alternative way to produce structurally defined CS was performed by employing a chemoenzymatic strategy for regioselective desulfation using a recombinant 4-O-endo-sulfatase from B. thetaioaomicron [163].

Regarding the sulfate donor for sulftotransferases, PAPS, a chemoenzymatic synthesis [164], enzymatic [165] or in vivo production using engineered E. coli [166] are recent attractable strategies to supply this co-factor for the synthesis of CS. These strategies have been applied for CS-A synthesis in vitro [166] and in vivo [160].

Drawbacks of the enzymatic CS synthesis include difficulty in controlling glycosyltransferase and sulftotransferase activities for a homogenous compound with a defined sulfation pattern [136]. The chemoenzymatic CS synthesis can provide the flexibility of chemical synthesis along with the efficiency and selectivity offered by enzymes to produce more defined CS oligosaccharides [167]. Nevertheless, the poor availability of substrates and co-factors, the poor enzymes activity and consequent low CS yields are still major limitations for the implementation of enzymatic and chemoenzymatic methods at industrial scale [168].

5. Microbial production of GAGs

Biotechnological processes using microorganisms have been developed for the production of GAGs and its oligosaccharides, based on the ability of certain pathogenic microbes to produce them. This strategy offers several advantages over animal extraction or chemical synthesis, such as avoiding using expensive substrates and environment-hazard chemicals, avoiding interspecies infection or contaminations, improving homogeneity, and precisely controlling the degree of sulfation and molecular weight [1]. The main benefit of producing GAGs in vivo over the enzymatic methods is taking advantage of biological machinery to avoid the use of expensive substrates and co-factors (and instead use cheap simple carbon sources as substrates). However, the industrial biotechnological production of GAGs, and specially of sulfated GAGs such as CS, is limited due to safety concerns for culturing pathogenic microorganisms and low yields [169]. Therefore, research efforts have been focused on the improvement of the production process, as well as on the design of better microbial cell factories for production of GAGs. An overview on the metabolic pathways from native microbial GAG producers will be provided, which can give insights on the design of biosynthetic pathways for chondroitin and CS production. Then it is discussed the current state of the biotechnological production of chondroitin and CS. In Table 3, advantages and disadvantages of the available chondroitin production methods are summarized.

5.1. Biosynthetic pathways for microbial GAGs production

As already mentioned, native microbial GAG and GAG-like producers are pathogens that use these compounds as constituents of their capsule to camouflage their infection and improve pathogenicity [6]. In these microorganisms, the genes involved in the capsular polysaccharide production from UDP-sugars and its transport are usually expressed in the form of an operon. The pathways for the biosynthesis of microbial GAGs are represented in Fig. 3. Representative native GAG-producers are E. coli K4 for chondroitin, E. coli K5 for heparosan, and P. multocida type A for HA. Capsular polysaccharide synthesis gene cluster includes three functional regions. Region 1 and region 3 are mainly responsible for the modification, transport, and localization of newly synthesized polysaccharide chain. Region 2 is mostly responsible for encoding enzymes related to the synthesis of polysaccharides and their precursors, so it is the most variable region across strains, according to the capsular GAG produced. The polymerization of these capsular polysaccharides occurs entirely on the cytoplasm through the action of glycosyltransferases followed by transportation, known to be adenosine triphosphate (ATP)-binding cassette (ABC) transporter-dependent [4, 170, 171, 172].
5.2. Current state of biotechnological GAGs production using microbes

Organisms producing other GAGs may comprise an important source of genes with relevance for the chondroitin heterologous pathway given that the majority of the steps involved in such production are the same. HA is naturally produced by Streptococcus group A or C and by P. multocida type A [6, 172, 173, 174, 175, 176]. The genes required for HA biosynthesis are encoded by the HA synthesis (HAS) operon (hasA-E) in Streptococci. Since HA does not require modifications after polymerization, the product from the fermentation can be directly isolated and purified. Commercial HA has been obtained mainly by microbial fermentation of Streptococcus equi and S. zooepidermidis [176, 177].

![Diagram: Production of glycosaminoglycans in microbes and its possible use in the biosynthesis of microbial chondroitin, hyaluronic acid or heparosan.]

**Table 3**

| Advantages and disadvantages of different chondroitin and chondroitin derivatives production methods. |
|---|---|---|---|
| Animal extraction | Chemical synthesis | Enzymatic production | Microbial production |
| **Substrate cost** | Cheap | Expensive | Expensive | Cheap |
| **Shortage of materials** | Yes | No | No | No |
| **Presence of contaminants (prions, viruses, growth factors)** | Yes | No | No | No |
| **Vegan/vegetarian** | No | Yes | Yes | Yes |
| **Requires feeding co-factors** | No | Yes | No | Yes |
| **Chemical steps to obtain substrates or sulfation** | No | Yes | Most times | Sometimes |
| **Steroselective and regioselective reactions** | not applicable | No | Yes | Yes |
| **Time-consuming process** | Yes | Yes, for protein purification | No | No |
| **Harsh conditions (pH, temperature, pressure)** | Yes | Limited and expensive | Difficult | Easy |
| **Control of degree of sulfation and size** | No | Yes | Yes | Yes |
| **Yields** | Highest | Low | Lowest | Low |
| **Environmental-friendly process** | No | No | Yes | Yes |
| **Possibility to obtain unnatural compounds** | No | Yes | Yes | Yes |
| **Final product purification complexity** | Very heterogeneous, polydisperse and usually contaminated with other glycosaminoglycans | Easy | Easy | May require cell lysis and purification. For pathogenic hosts, endotoxins need to be removed |

**Fig. 3.** Production of glycosaminoglycans in microbes and its possible use in the biosynthesis of microbial chondroitin, hyaluronic acid or heparosan. Depending on the microbial host, the heterologous expression of the enzymes shown in orange boxes might be required for glycosaminoglycans production. Enzyme abbreviations: ABC, adenosine triphosphate (ATP)-binding cassette transporters; Aldo, fructose-6-phosphate aldolase; Fbp, fructose-1, 6-bisphosphatase; GalU, uridine triphosphate:glucose-1-phosphate uridylyltransferase; Glk, glucokinase; GlmM, phosphoglucomamine mutase; GlmS, glucoseamine-6-phosphate synthase; GlmU, glucosamine-1-phosphate N-acetyltransferase/N-acetylglucosamine-1-phosphate uridylyltransferase; GipF, Glycerol uptake facilitator protein; GipK, glycerol kinase; Gpd, glyceraldehyde-3-phosphate dehydrogenase; HasA, hyaluranan synthase; Kfa, β-1, 3-glucuronyltransferase; Kfc, n-1, 4-N-acetylgalactosaminyltransferase; KfcC, chondroitin synthase; Pfk, 6-phosphofructokinase; Pgi, glucose-6-phosphate isomerase; Pgm, phosphoglucomutase; PTS, phosphotransferase system; Uae, UDP-N-acetylgalactosamine 4-epimerase; UGD, uridine diphosphate (UDP)-glucose 6-dehydrogenase.
Industrial production of sulfated GAGs is more challenging because it requires post-polymerization modifications of the microbially-produced polysaccharide backbone.

Bio-synthesis of HP from microbial sources requires the microbial production of the precursor heparan [178, 179, 180] with further chemical and/or enzymatic modifications [19, 181, 182, 183, 184]. E. coli K5, P. multocida type D and Avibacterium paragallinarum genotype II can synthesize heparan [35, 36, 185, 186]. High titers of heparan have been achieved using E. coli K5 (up to 15 g/L in bioreactor) [178, 179] which has the heparan biosynthetic genes encoding glycosyltransferases and dehydrogenases organized in an operon (kfoA-D, Fig. 3). Regarding DS and KS, there have been no reports on their production using microorganisms.

Unsulfated chondroitin, a starting material for CS, is produced by P. multocida type F and A. paragallinarum genotype I [35, 36]. The pathogenic strain E. coli K4 natively synthesizes a capsular polysaccharide that shares a similar structure with the unsulfated chondroitin, but contains a residue of fructose [187]. Table 4 presents recent reported studies on in vivo production of chondroitin and CS, including in native producers and in heterologous hosts. E. coli K4 became the first and most studied microorganism to be used for the biotechnological production of chondroitin [37]. In fact, food grade CS has been industrially produced by microbial fermentation. The native producer E. coli K4 is used to produce microbial K4 polysaccharide followed by its chemical defructosylation and regioselective sulfation into CS sodium. The product is sold under the name of Mythocondroitin™ (marketed since 2017 by Gnosis S.p.A., which was acquired by Lesaffre in 2018).

The genes required for fructosylated chondroitin production and transportation in E. coli K4 are organized in an operon containing kfoA-G genes. From the seven constituent genes, the most relevant genes in the biosynthesis of fructosylated chondroitin are: kfoA encoding UDP-GlcNAc 4-epimerase that provides UDP-GalNAc; kfoC encoding chondroitin synthase (homolog to PmCS); and kfoF encoding UDP-glucose dehydrogenase that provides UDP-GlcA. Fructosylated chondroitin can undergo a subsequent step of hydrolysis of fructose monomer and chemical sulfation [188, 189, 190]. The identification of the enzyme responsible for inserting the fructose residue (KfoF, fructosyltransferase) and its consequent deletion led to the production of unsulfated chondroitin [191]. Genetic engineering has been applied to E. coli K4 to further improve the polysaccharide yields [61, 63, 187, 190, 192, 193, 194, 195]. In fact, the highest reported yields so far for biotechnological production of chondroitin have been achieved with genetically engineered E. coli K4 through fed-batch fermentations, reaching 8.43 – 9.2 g/L of fructosylated chondroitin [187, 192]. Feeding alternative synthetic precursors to the fermentation medium is a possible strategy to further improve the polysaccharide yields [61, 63, 187, 190, 192, 193, 194, 195].

The first study aiming to produce chondroitin in a heterologous host used the pathogenic bacteria E. coli K5 expressing kfoC and kfoA from E. coli K4 and 52.6 mg/L of chondroitin was produced without the need for defructosylation [197]. Other pathogen, HA producer S. zooplaedemius, was also attempted as an heterologous host for chondroitin using the same genes [176] but it also resulted in low yields (300 mg/L).

To avoid the contamination of the final product with virulence factors and toxins and to eliminate the defructosylation step, alternative microorganisms have been engineered with K4 polysaccharide production pathway. The chondroitin production in non-pathogenic heterologous hosts has been achieved in E. coli BL21 (DE3) [198], B. subtilis [158, 180, 199], Corynebacterium glutamicum [200] and E. coli K-12 [160, 201]. Using safer heterologous hosts, the highest chondroitin yield reported (2.4 g/L) was achieved by expressing kfoC, kfoA, kfoF in E. coli BL21 using the high copy number vector pETM6, with a pseudo-operon gene configuration [198].

The chondroitin backbone can be further modified through the action of various sulfotransferases to produce CS, or it can undergo epimerization of GlcA into IdOA and subsequent sulfation to generate DS. Several studies combined the microbial in vivo production of chondroitin with enzymatic or chemical strategies to produce CS [158, 166, 202]. By combining the in vivo production of chondroitin backbone and in vitro enzymatic sulfation, CS-A and CS-C production has been achieved [158]. Bacillus subtilis harboring the kfoA and kfoC genes from E. coli K4 was engineered. E. coli was used to express rat aryl sulfotransferase IV (ASST IV) and P. pastoris was the expression host for mouse C4OST and C6OST sulfotransferases.

In the work of Erenler [202], a non-pathogenic E. coli strain was engineered to express a previously described biosynthetic pathway for chondroitin production [198] along with a Vibrioceila hemoglobin gene (ggh) whose expression has previously been reported to provide benefits to bacteria growth and recombinant protein expression and improved accumulation of different biopolymers [203]. The authors produced and purified the microbial chondroitin and performed chemical sulfation. Recently, the construction of the complete pathway for in vivo production of sulfated chondroitin in E. coli has been reported [160]. The authors evaluated both E. coli K4 and K-12 (containing K4 kfoCAF chondroitin genes) with expression of C4OST and PAPS reductase (cysH) deletion (to improve the pool of sulfate donor PAPS) for CS production. Only E. coli K4 was able to produce extracellular CS (10.76 μg/L in shaken flasks), and the intracellular yield was also higher than the one found for the engineered E. coli K-12. However, the percentage of sulfation of intracellular CS was 36% higher in the K-12 strain. After improving the activity of C4OST through mutation, optimizing growth and C4OST induction conditions, and inhibiting transport system through clustered regularly interspaced short palindromic repeats interference (CRISPRi), the levels of sulfation (~55%) reached the same ones achieved in K-12. The authors also optimized the fermentation process in bioreactor using K-12 which resulted in 27 μg/L dry cell weight in Intracellular CS-A with a sulfation degree of 96%, a level of 4-O-sulfation similar to the ones found in animals. More recently, P. pastoris has been successfully engineered towards the production of CS-A using methanol as substrate [204]. The expression of kfoC and kfoA from E. coli K4, tuaD from B. subtilis, engineered mouse C4OST and overexpression of endogenous genes coding adenosine-5′-triphosphate sulfurylase (ATPS) and adenosine-5′-phosphosulfate kinase (APSK) to improve PAPS supply and sulfation, resulted in a production of 2.1 g/L. CS-A with 4.0% sulfation using a fed-batch fermentation. The integrated approach from these two recent studies [160, 204] provides significant cost reduction to the process. However, the CS yields in E. coli are still low while the CS produced by engineered P. pastoris has a low sulfation degree. Therefore, more efforts are required to genetically improve the host and to optimize the process towards interesting yields and sulfation degrees for biotechnological applications.

5.3. Metabolic engineering to optimize CS production

Despite the recent advances on biotechnological production of CS, the yields are still not sufficient to meet the increasing demand of this widely used nutraceutical. Metabolic engineering of the host microorganisms for improving CS precursors (UDP-GlcA, UDP-GlcNAc and UDP-GalNAc) production pathways should be performed to improve intermediate pools and their subsequent availability.

In order to redirect the metabolic flux towards chondroitin or CS production in microbes, the most obvious modification is the overexpression of chondroitin polymerase/synthase which in E. coli K4 is encoded by kfoC. When kfoC was overexpressed in E. coli K4 using plasmids, the fructosylated chondroitin yield improved 2-fold compared to the wild-type [61]. When the kfoC overexpression was IS2 transposon-mediated, the K4 production was 2.5 times higher than the wild-type [205]. Strategies to improve KfoC enzymatic activity have also
| GAG                        | Host                          | Substrate(s)          | Genetic modification(s)                          | Process (working volume)                          | Maximal yield (mg/L) | Reference |
|---------------------------|-------------------------------|-----------------------|-------------------------------------------------|------------------------------------------------|----------------------|-----------|
| Fructosylated chondroitin | E. coli O5:K4:H4              | Glycerol/ glucose     | Insertion of multiple copies of the autologous rfaH gene | Shake flask/ Batch (2.5 L) Three-phase fermentation (2.5 L); batch-fed batch in microfiltration regimen | 280/300 475/525 4000/5100 8400/9200 | [192]    |
|                           |                               |                       |                                                 | Three-phase fermentation (1000 L)                  | 9000/ (not tested with glucose) |          |
|                           | E. coli O5:K4:H4              | Glycerol/ glucose     | Overexpression of rfaH                          | Shake-flask (200 mL)/ Batch (2 L)                  | 212/283              | [63]      |
|                           |                               |                       |                                                 | Fed-batch (2 L)                                   | 466                  |           |
|                           | E. coli O5:K4:H4              | Glycerol              | Overexpression of the transcriptional regulator sLyA | Shake-flask (70 mL)/ Batch (4 L)                   | 302 (plasmid) 425 (integrative) 3470 (integrative) | [205]    |
|                           | E. coli O5:K4:H4              | Glycerol              | IS2 transposon-mediated kfoC overexpression     | Shake-flask (200 mL)/ Batch (4 mL)                 | 391                  | [194]    |
|                           | E. coli O5:K4:H4              | Glycerol              | PfkA deletion, overexpression of pgm, galU, glmM and mutated kfoC, and RBS optimization | Fed-batch (30 L)                                   | 8430                 | [187]    |
| Fructosylated chondroitin | E. coli O5:K4:H4              | Glycerol              | Overexpression of kfoA and kfoF glmM, glmS        | Batch (2 L)                                        | 3990                 | [206]    |
|                           |                               |                       |                                                 | Fed-batch (2 L)                                   | 2090                 |           |
|                           | E. coli O5:K4:H4              | Glycerol              | Overexpression of pgm, galU and kfoF             | Fed-batch (2 L)                                   | 2140                 | [190]    |
|                           | E. coli O5:K4:H4              | Glucose               | Overexpression of kfoA and kfoF glmM, glmS        | Batch in microfermenter (4 mL) and in bioreactor (1.8 L) | 315 (microfermenter); 300 (bioreactor) | [195]    |
|                           |                               |                       |                                                 | Fed-batch microfermenter (3 mL) and in bioreactor (1.6 L) | 1410 (microfermenter); 1570 (bioreactor) |          |
|                           | E. coli O10:K5:H4/S. equi subsp. snoopidemicus | Glucose              | kfoC and kfoA expression                         | Shake flask (20 mL)/ Shake-flask (0.6 L)/ Batch (1.6 L) | 52.6 90 300 | [197]    |
|                           | E. coli BL21 Star (DE3)       | Glucose               | KfoC, KfoA and KfoF expression in pseudo-operon gene configuration | Shake flask (25 mL)/ Fed-batch (1 L)              | 213 2400             | [198]    |
|                           | B. subtilis 168               | Sucrose               | KfoC, KfoA expression and tuaD up-regulation     | Shake flask (50 mL)/ Fed-batch (1.35 L)/ Fed-batch (2 L) | 2540 5220 1910 | [180]    |
|                           | Corynebacterium glutamicum    | Glucose               | KfoC, KfoA expression (codon-optimized), kfo deletion, and ugd overexpression | Fed-batch (0.2 L)                                   | ~2500                | [201]    |
| Furyl-terminated chondroitin| E. coli DH1 (K-12 derivative, lacking kps genes) | Glucose-glycerol- lactosides | Expression of kfoC, KfoG, wbpF, KfoD and mouse gcaAT | Fed-batch (0.2 L)                                   | ~2500                | [202]    |
| Chondroitin sulfate A     | E. coli C2987                 | Catabolizable amino acids from LB | Expression of kfoA, KfoG, KfoF (plasmid from [198]) and vgb | Shake flask (25 mL); Chemical sulfation | Not reported | [182]    |
| Chondroitin sulfate A and C| B. subtilis (chondroitin production) | Sucrose               | Expression of tuaD, glmU, glmT, glmS, and KfoA from B. subtilis E168c [180]; expression of ASST IV, C4OST and C6OST for sulfation | Fed-batch (1.35 L); Enzymatic sulfation | 7150 | [158]    |
| Chondroitin sulfate A     | E. coli O5:K4:H4 (chondroitin) |                               | KfoA deletion in E. coli K4 for chondroitin backbone | Not reported for in vivo production                 |                      | [166]    |

(continued on next page)
been addressed. By using random mutagenesis it was possible to improve KfoC activity (R313Q) that led to 82% improvement on fructosylated chondroitin over the wild-type [207].

Regulatory elements of expression of the bacterial GAG-like polysaccharides have also been targets for genetic engineering. The overexpression of the transcriptional activators rfaH [63] and slyA [194] have enhanced the expression of capsular genes and consequently improved E. coli K4 polysaccharide production by 58% and by a 1.5-fold, respectively, over the wild-type. RfaH acts on capsular gene cluster by preventing the transcript termination of genes related to the modification, transport, and localization of newly synthesized polysaccharide chain (region 3 genes), and consequently improve the expression of genes related to the synthesis of polysaccharides and their precursors (region 2 genes) [208]. SlyA activates the transcription of the whole capsular gene operon [194].

Regarding the precursor availability, balancing UDP-sugars is an established strategy for metabolic engineering of HA [209] and fructosylated chondroitin [187]. The genes pgm, galU and ugd/kfoF (encoding phosphoglucomutase, uridine triphosphate-glucose-1-phosphate uridylyltransferase, and UDP-glucose dehydrogenase, respectively) for UDP-GlcA synthesis and glmS, glmM and glmU (encoding glucosamine-6-phosphate synthase, phosphoglucosamine mutase and glucosamine-1-phosphate N-acetyltransferase/N-acetylglycosamine-1-phosphate uridylyltransferase, respectively) for UDP-GalNAc production might be interesting targets for overexpression (Fig. 3). Overexpression of these genes have resulted in improved production of K4 and other polysaccharides. Levander and coworkers [210] found that the overexpression of the endogenous galU gene in S. thermophilus LY03 led to a 10-fold increase in galU activity, however exopolysaccharide yield was not affected. Nevertheless, when galU was overexpressed in combination with pgmA (pgm homolog), the exopolysaccharide yield increased.

Overexpression of pgm and galU in E. coli AD202 also resulted in increased UDP-galactose derived disaccharides from 2.5 mM to 20 mM by improvement of carbon flux through UDP-glucose synthesis pathway [211]. Engineering E. coli K4 with one copy of endogenous genes pgm and galU also improved capsular polysaccharide production [65]. The authors further increased capsular polysaccharide yields in 45% using glutamine supplementation to boost UDP-GalNAc precursor production [65, 63]. Engineering Saccharomyces cerevisiae with the endogenous genes pgm2 and ugp1 (equivalent to galU) resulted in a 17% improvement of scutellarein 7-O-glucoside production rate by improving UDP-glucose pool [212]. Overexpressing glmM and glmU genes resulted in higher capsular polysaccharide production in E. coli K4 [206]. Despite the step catalyzed by ugd-codified enzyme was considered in previous works as the limiting factor of GAG biosynthesis in homologous and heterologous organisms [61, 180, 213, 214], few examples evaluating alternative genes for this step have been reported, possibly missing interesting catalysts.

On the other hand, the repression of genes from competing pathways can also be beneficial for redirecting the metabolic flux towards the production of GAG precursors. Down-regulating the expression of three genes (glucose-6-phosphate 1-dehydrogenase zwf, adenine triphosphate-dependent 6-phosphofructokinase pfkA, and glmM) that control the major competing reactions (cell wall recycling pathways) of GlcNAc synthesis by CRISPRi improved GlcNAc titer in B. subtilis [215]. Silencing zwf and pfkA also resulted in improved HA production in B. subtilis [216]. By favoring the production of fructose 6-phosphate, pfkA knock-out resulted in increased chondroitin production in E. coli K4 [187].

Combination of both repression and activation can provide optimized microbial cell flux towards GAGs production. Knock-out of pfkA and zwf genes coupled with overexpression of the genes galU-ugd and...
glmS-glmM-glmU improved HA production [217] in E. coli K-12 W3110 harboring HA synthase gene (hasA) from S. zoosporaeformis, and with transcriptional repressors genes galR and galS deleted.

When the intended biosynthetic pathway has intermediates that are critical for biomass production, as it is the case for chondroitin, redirecting the carbon flux might result in lower yield and growth rate. To assess this question, there have been interesting advances on dynamical control to balance the metabolic flux according to the intermediate concentration. This strategy has been applied for overproduction of GlcNAc in B. subtilis which consisted in engineering the native glucosamine-6-phosphate responsive glmS ribosome switch to act as a sensor and dynamically control the metabolic flux [218]. This strategy increased about 2-fold the native GlcNAc titer, being a potential strategy to improve chondroitin producing strains.

Finally, computational methods can be useful to aid on the prediction of potential targets for improving CS production in heterologous hosts. The use of stoichiometric or kinetic models of the heterologous host to perform in silico predictions has been shown to be useful to guide engineering strategies towards the improved production of valuable compounds. In fact, a computational approach was already performed to engineer an optimal HA production in C. glutamicum [219].

Sophisticated genetic engineering tools for genome editing, such as CRISPR [220], are shown to be rapid and cost-effective and, therefore, can be implemented on the intended system to generate engineered hosts with improved chondroitin production.

5.4. Alternative hosts

Alternative hosts can provide more suitable platforms for CS production. Besides replacing the native pathogenic bacteria and, consequently, avoiding the presence of virulence factors in the final product, the application of industrially used E. coli, B. subtilis, and Corynebacterium for CS production has the advantages of being fast-growing organisms, with well-characterized genetic and physiological backgrounds, and many available tools for gene expression and genome editing [221].

However, biosynthetic enzymes expressed in bacterial systems usually present low solubility, stability, and activity, which may limit CS synthesis. On the other hand, enzymes expressed in eukaryotes typically show enhanced activity but are expressed at lower amounts [167]. Specially for the expression of eukaryotic genes, in particular sulfotransferases, eukaryotic microbial cells such as the broadly used S. cerevisiae and P. pastoris can provide beneficial conditions regarding codon preference, enzyme folding and glycosylation patterns more similar to the original enzymes. Also, since mammalian CHO cells have shown to be able to produce HP [222], animal cell fermentation can also be a possible, however expensive, alternative strategy for the production of CS.

5.5. Additional optimization strategies

Besides the metabolic engineering strategies to improve intermediate pools, or the use of alternative hosts, other approaches to make biotechnological CS production more cost-effective include screening for more efficient enzymes, modification of the enzymes through protein engineering and immobilization to improve activity and productivity. Also, salvage pathways can be added to improve precursors – for example, UDP-GlcA can also be produced in two different ways directly from GlcA using glucuronokinase, UDP-sugar pyrophosphorylase, and inorganic phosphatase instead of depending on UDP-glucose conversion through ugd step. Increasing energy through ATP supply, and implementing ATP regeneration systems can also benefit the CS in vivo production. The control of CS molecular weight in fermentation is also desirable to achieve a more monodisperse product [190, 223]. In addition, optimization of the fermentation process, media composition, temperature and pH conditions have been shown to be effective for improved GAG yields [178, 224]. Using low-cost media can provide a more competitive process, namely agro-industrial by-products such as sugarcane molasses and corn steep liquor which have already been used for HA production [225, 226, 227], therefore they present potential applicability for CS production. Additionally, engineering of CS transport can aid to improve CS titers, by even repressing transporters for increased CS intracellular in vivo sulfation [160], or by contrarily strengthening cell CS exportation, which would be more valuable from an industrial point of view but would require the extracellular expression of the sulfotransferases. Finally, optimizing environmental conditions for maximal enzyme activity to perform the post-polymerization modifications of biotechnological CS polysaccharides in vivo or in vitro would aid to obtain a final commercial sulfated product at competitive yields.

6. Conclusions and future perspectives

Compared to animal-derived products, heterologous microbes can provide pathogen-free chondroitin without the use of hazardous chemicals. With the increasing applications of CS, the studies on its microbial production have been growing with much focus on the native GAG producers’ pathway to polymerize the backbone starting material, and on its post-polymerization modifications through enzymatic in vitro reactions. However, there are bottlenecks such as insufficient supply of precursors, low activity and/or stability of the enzymes and difficult and costly sulfotransferase enzymes purification. Strategies that can help solving these issues include genetic engineering for improving the precursors pool and transport; evaluation of alternative hosts for efficient expression of enzymes (since most genes required for sulfated GAGs production are from animals, expression in eukaryotic hosts could provide more soluble and active enzymes); improvement of enzyme activity and solubility through enzyme engineering and environment optimization; and the use of integrated approaches of microbial production and post-polymerization. The knowledge improvement on GAGs enzymes for polymerization, transport and post-polymerization, together with the development of efficient technologies for gene editing, are expected to lead to the establishment of efficient microbial cell factories for the CS production.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This study was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UIDB/04469/2020 unit. The authors acknowledge FCT for funding the doctoral grant SFRH/BD/132998/2017 to Couto, M. R.
References

[1] Z. Kang, Z. Zhou, Y. Wang, H. Huang, G. Du, J. Chen, Bio-based strategies for producing glycosaminoglycans and their oligosaccharides, Trends Biotechnol 36 (2018) 806–818, https://doi.org/10.1016/j.tibtech.2018.03.010.

[2] M. Mende, C. Bednarek, M. Wawryszyn, P. Sauter, U. Schepers, U. Schepers, Mass spectrometry: important role in glycosaminoglycan research, Biotechnology Reports 33 (2022) e00710, https://doi.org/10.1016/j.btre.2021.100010.

[3] J. Casale, J.S. Crane, Biochemistry, Glycosaminoglycans, StatPubs Publishing, Treasure Island (FL), 2021, https://www.ncbi.nlm.nih.gov/pubmed/31335015 (accessed July 4, 2021).

[4] A. Varzi, R.D. Cummings, J.D. Eko, P. Stanley, G.W. Hart, A. Arbi, A.G. Darvill, T. Kinosita, N.H. Packer, J.H. Prestegard, R.L. Schnaar, P.H. Seeger, Essentials of Glycobiology, Cold Spring Harb (2017) 823, https://www.ncbi.nlm.nih.gov/books/NBK330274/ (accessed July 24, 2021).

[5] J. Kovensky, E.C. Littrell, U. Schepers, Applications of glycosaminoglycans in the medical, veterinary, pharmaceutical, and cosmetic fields, in: S.N. Goyanes, N. D’Accorso (Eds.), Ind. Appl. Renew. Biomass Prod., Springer International Publishing, Cham, 2017, pp. 135–164, https://doi.org/10.1007/978-3-319-61288-1_5.

[6] B.F. Cress, J.A. Englaender, W. He, D. Kasper, R.J. Linhardt, M.A.G. Koffas, Starch and starch-like glycogenes from marine and terrestrial sources: extraction and purification methods, Carbohydr. Polym. 243 (2020), 116441, https://doi.org/10.1016/j.carbpol.2021.117971.

[7] K.W. Chang, S.F. Weng, Y.H. Tseng, UDP-glucose dehydrogenase gene of Xanthomonas campestris is required for virulence, Biochem. Biophys. Res. Commun. 287 (2001) 500–505, https://doi.org/10.1006/bbrc.2001.5991.

[8] L. Guan, L. Zhang, X. Yue, J. Xiang, Z. Zhao, Molecular pathogenesis of the hyaluronic acid capsule of Pasteurella multocida, Microb. Pathog. 149 (2020), 104830, https://doi.org/10.1016/j.micpath.2020.104830.

[9] A. Kiviet, G. Zhu, G. Greth, M. Mende, M. Hanke, Glycosaminoglycans: a review, J. Tissue Eng. Regen. Med. 12 (2018) e23–e41, https://doi.org/10.1002/term.2398.

[10] N. Volpi, Therapeutic Applications of glycosaminoglycans, Curr. Med. Chem. 13 (2006) 1799–1810, https://doi.org/10.2174/092986706777745240.

[11] F. Zhang, Z. Zhang, R.J. Linhardt, Glycosaminoglycans, in: Handbook of Glycamics, 2009: pp. 59–80. https://doi.org/10.1087/n978-12-375660-000312-0.

[12] M.M. Abdallah, N. Fernández, A.A. Mattias, M. do R. Bronze, Hyaluronic acid and chondroitin sulfate from marine and terrestrial sources: extraction and purification methods, Carbohydr. Polym. 243 (2020), 116441, https://doi.org/10.1016/j.carbpol.2020.116441.

[13] D. Cimini, O.F. Restaino, C. Schiraldi, Microbial production and metabolic engineering of chondroitin and chondroitin sulfate in E. coli, Emerging Top. Life Sci. (2018) 349–361, https://doi.org/10.1038/s41420-2018-000166.

[14] T. Rian, Y. Liu, L. Liu, Microbial production of oligosaccharides and polysaccharides, in: L. Liu, J. Chen (Eds.), Systems and Synthetic Biotechnology Production of Nutraceuticals, Springer Singapore, Singapore, 2019, pp. 75–91, https://doi.org/10.1007/978-981-15-0444-4_4.

[15] V.H. Vigne, P. Vignovich, A.V. González, A.A. Vázquez-Mayoralas, A. Iadonisi, Chondroitin, C. Chang, Analysis of the biosynthesis genes and chemical components of the capsule of Avibacterium paragallinarum, Vet. Microbiol. 145 (2010) 90–99, https://doi.org/10.1016/j.vetmic.2010.03.002.

[16] P.L. DeAngelis, N.S. Gunay, T. Toida, W. Mao, R.J. Linhardt, Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively, Carbohydr. Res. 337 (2002) 1547–1552, https://doi.org/10.1016/S0008-115X(02)00423-1.

[17] J.-R. Wu, P.-Y. Chen, J.-H. Shi, C.-L. Shyu, H.K. Shieh, F. Chang, P.-C. Chang, Analysis of the biosynthesis genes and chemical components of the capsule of Avibacterium paragallinarum, Vet. Microbiol. 145 (2010) 90–99, https://doi.org/10.1016/j.vetmic.2010.03.002.

[18] D. Cimini, O.F. Restaino, A. Catapano, M. De Rosa, C. Schiraldi, Production of capsular polysaccharide from Escherichia coli k4 for biotechnological applications, Appl. Microbiol. Biotechnol. 85 (2010) 1779–1787, https://doi.org/10.1007/s00253-010-2281-9.

[19] V. Gargiulo, L. Ranzetta, M. Parrilli, C. De Castro, Structural analysis of chondroitin sulfate from Scyliorhinus canicula: a useful source of this glycosaminoglycan, J. Biomol. Struct. Dyn. 6 (2015) 1249–1252, https://doi.org/10.1080/07391102.2015.104321.

[20] M. Mende, C. Bednarek, M. Wawryszyn, P. Sauter, U. Schepers, U. Schepers, Mass spectrometry: important role in glycosaminoglycan research, Biotechnology Reports 33 (2022) e00710, https://doi.org/10.1016/j.btre.2021.100010.

[21] P. Datta, R.J. Linhardt, S.T. Sharfstein, Industrial production of chondroitin sulfate from marine and terrestrial sources: extraction and purification methods, Carbohydr. Polym. 243 (2020), 116441, https://doi.org/10.1016/j.carbpol.2020.116441.

[22] M. Mende, C. Bednarek, M. Wawryszyn, P. Sauter, U. Schepers, U. Schepers, Mass spectrometry: important role in glycosaminoglycan research, Biotechnology Reports 33 (2022) e00710, https://doi.org/10.1016/j.btre.2021.100010.
[218] T. Niu, Y. Liu, J. Li, M. Koffas, G. Du, H.S. Alper, L. Liu, Engineering a glucosamine-6-phosphate responsive glmS ribozyme switch enables dynamic control of metabolic flux in Bacillus subtilis for overproduction of N-acetylglucosamine, ACS Synth. Biol. 7 (2018) 2423–2435, https://doi.org/10.1021/acssynbio.8b00196.

[219] F. Cheng, H. Yu, G. Stephanopoulos, Engineering Corynebacterium glutamicum for high-titer biosynthesis of hyaluronic acid, Metab. Eng. 55 (2019) 276–289, https://doi.org/10.1016/j.ymben.2019.07.001.

[220] J. Rainha, J.L. Rodrigues, L.R. Rodrigues, CRISPR-Cas9: a powerful tool to efficiently engineer Saccharomyces cerevisiae, Life 11 (2021) 1–16, https://doi.org/10.3390/life11010013.

[221] A. Williams, R.J. Linhardt, M.A.G. Koffas, Metabolic engineering of capsular polysaccharides, Emerg. Top. Life Sci. 2 (2018) 337–348, https://doi.org/10.1042/ETLS20180003.

[222] J.Y. Baik, L. Gasimli, B. Yang, P. Datta, F. Zhang, C.A. Glass, J.D. Esko, R.J. Linhardt, S.T. Sharfstein, Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin, Metab. Eng. 14 (2012) 81–90, https://doi.org/10.1016/j.ymben.2012.01.008.

[223] O.F. Restaino, S. D'ambrusio, E. Cassese, S.B. Ferraiuolo, A. Alfano, R. Ventriglia, A. Marrazzo, C. Schiraldi, D. Cimini, Molecular weight determination of heparosan- and chondroitin-like capsular polysaccharides: figuring out differences between wild-type and engineered Escherichia coli strains, Appl. Microbiol. Biotechnol. 103 (2019) 6771–6782, https://doi.org/10.1007/s00253-019-09969-8.

[224] O.F. Restaino, D. Cimini, M. De Rosa, A. Catapano, M. De Rosa, C. Schiraldi, High cell density cultivation of Escherichia coli K4 in a microfiltration bioreactor: a step towards improvement of chondroitin precursor production, Microb. Cell Fact. 10 (2011) 1–10, https://doi.org/10.1186/1475-2859-10-10.

[225] I.R. Amado, J.A. Vázquez, L. Pastrana, J.A. Teixeira, Cheese whey: a cost-effective alternative for hyaluronic acid production by Streptococcus zooepidemicus, Food Chem 198 (2016) 54–61, https://doi.org/10.1016/j.foodchem.2015.11.062.

[226] I.R. Amado, J.A. Vázquez, L. Pastrana, J.A. Teixeira, Microbial production of hyaluronic acid from agro-industrial by-products: molasses and corn steep liquor, Biochem. Eng. J. 117 (2017) 181–187, https://doi.org/10.1016/j.bej.2016.09.017.

[227] N.C. Pan, H.C.B. Pereira, M.L.C. da Silva, A.F.D. Vasconcelos, M.A.P.C. Celligoi, Improvement production of hyaluronic acid by Streptococcus zooepidemicus in sugarcane molasses, Appl. Biochem. Biotechnol. 182 (2017) 276–293, https://doi.org/10.1007/s12010-016-2326-y.